Ontario Hospital Research Labs Sourced Dogs from U.S. Breeder with Troubled History
An investigation has revealed that at least two prominent Canadian hospital research laboratories have imported dogs for scientific experimentation from a United States breeding facility with a documented history of animal care violations. This discovery emerges amid ongoing ethical debates within the scientific community and legislative bodies regarding the necessity of animal testing in research.
Scale of Research Dog Imports and Problematic Supplier
According to data from the Canadian Border Services Agency, more than 17,800 dogs entered Canada from the United States specifically for research purposes between 2019 and 2025. Among the suppliers was Marshall BioResources, an industrial-scale breeding operation located in upstate New York. Federal inspectors have cited Marshall for multiple violations between 2021 and 2024, including injuries and sores on animals, mould-covered food provisions, and cages filled with feces. In total, inspectors documented 11 separate violations involving numerous dogs and cats at the facility.
Canadian Hospitals' Connections to Controversial Breeder
The University Health Network (UHN) in Toronto, which states it discontinued all dog research in 2020, and the Lawson Health Research Institute in London, Ontario, which recently terminated its dog testing program, were both past customers of Marshall BioResources. A UHN cancer research study published in July 2025 explicitly noted that "sexually mature male beagle dogs were purchased from Marshall BioResources."
Brad Wouters, UHN's executive vice-president of science and research, explained in a statement that the research referenced in the 2025 publication was conducted in 2019. He emphasized that UHN has not engaged in any research involving dogs or cats for over six years and therefore cannot comment on allegations concerning breeders. Wouters stated that at the time of the study, the research adhered to all institutional guidelines and oversight processes.
Regulatory Framework and Shifting Research Practices
In Canada, guidelines for acquiring purpose-bred research dogs are established by the Canadian Council on Animal Care (CCAC), a federal non-profit organization that supervises animal use in scientific research. The CCAC mandates that animals must be obtained from credible suppliers "whose reputation is based on humane, safe and timely supply and transport of healthy animals."
Wouters indicated that UHN ceased using dogs in medical research because "with the advancement of research techniques, scientists are increasingly using innovative models." This shift reflects a broader trend in the scientific community toward alternative research methodologies that reduce or eliminate animal testing.
Closure of Dog Testing Program at Lawson Health
The Lawson Health Research Institute, based at St. Joseph's Health Care in London, utilized dogs in scientific research for several decades, with some animals sourced from Marshall BioResources. The institute shut down its dog testing program in the summer of 2025 following investigative reports detailing procedures that included inducing heart attacks in dogs lasting up to three hours.
A subsequent hospital review concluded that St. Joseph's had met regulatory and scientific standards but identified deficiencies in public communication and governance issues. In an unattributed statement provided to investigators, St. Joseph's indicated it is "developing an action plan to address all the findings and recommendations," including implementing policies to ensure its responsibilities are "understood and followed."
Broader Ethical Debate on Animal Experimentation
These revelations surface as scientists and lawmakers continue to deliberate the fundamental question of whether animals must be used for experiments at all. The ethical considerations surrounding animal testing, particularly involving dogs who are often chosen for their physiological similarities to humans, remain a contentious issue in medical research and policy development.
The case highlights the complex intersection of scientific advancement, ethical responsibility, and regulatory oversight in biomedical research, raising important questions about supply chain transparency and animal welfare standards in research institutions.
